194 related articles for article (PubMed ID: 1555257)
1. Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL.
Jicha DL; Schwarz S; Mulé JJ; Rosenberg SA
Cell Immunol; 1992 Apr; 141(1):71-83. PubMed ID: 1555257
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
Alderson MR; Sassenfeld HM; Widmer MB
J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
[TBL] [Abstract][Full Text] [Related]
3. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.
Lynch DH; Miller RE
J Exp Med; 1994 Jan; 179(1):31-42. PubMed ID: 8270874
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.
Jicha DL; Mulé JJ; Rosenberg SA
J Exp Med; 1991 Dec; 174(6):1511-5. PubMed ID: 1744582
[TBL] [Abstract][Full Text] [Related]
6. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
Puri RK; Leland P
Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
8. Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor.
Leshem B; Epstein E; Kedar E
Immunol Lett; 1989 Jan; 20(1):53-8. PubMed ID: 2785493
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
10. IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).
Ferrari G; King K; Rathbun K; Place CA; Packard MV; Bartlett JA; Bolognesi DP; Weinhold KJ
Clin Exp Immunol; 1995 Aug; 101(2):239-48. PubMed ID: 7544247
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
13. Effect of IL-2 in vitro on CTL generation in spleen cells of young and old mice: asialo GM1+ cells are required for the apparent restoration of the CTL response.
Bloom ET; Kubota LF
Cell Immunol; 1989 Mar; 119(1):73-84. PubMed ID: 2784081
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.
Roth AD; Dupuis S; Alberto P
Clin Exp Immunol; 1995 Aug; 101(2):362-8. PubMed ID: 7648722
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
16. Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
Sensi M; Bergomi M; Formelli F; Parmiani G
Int J Cancer; 1990 Dec; 46(6):1088-94. PubMed ID: 2249896
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.
Mulé JJ; Schwarz SL; Roberts AB; Sporn MB; Rosenberg SA
Cancer Immunol Immunother; 1988; 26(2):95-100. PubMed ID: 2452015
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. Implications for the age-related decline in CTL.
Bloom ET; Horvath JA
J Immunol; 1994 May; 152(9):4242-54. PubMed ID: 7908914
[TBL] [Abstract][Full Text] [Related]
19. Precursor frequency and lytic specificity of interleukin 2 and interleukin 4-responsive murine lymphocytes.
Widmer MB; Voice RF; Conlon PJ; Grabstein KH
Transplantation; 1990 Apr; 49(4):743-8. PubMed ID: 2139260
[TBL] [Abstract][Full Text] [Related]
20. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
